



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_51352
Title of the Manuscript:	A review of Genetic polymorphism of GSTs (glutathione –s transferase) genes in breast cancer
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Overall the paper is sound, but there are numerous errors in writing, spelling, grammar, and formatting that require careful editing. I also do not understand this – "disparate breast cancer incidence rates among American Caucasian" in the context of the sentence about differences in breast cancer incidences. What does that phrase mean exactly? What groups are considered and how are the rates disparate between them?	
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Michael Bordonaro
Department, University & Country	Geisinger Commonwealth School of Medicine, USA